PARP1 and ovarian cancer: 3‐aminobenzamide (3‐AB); Figure 5).[84] Bernges and Zeller reported that by inhibiting PARP activity with 3‐AB (PARP1 half‐inhibitory concentration, IC50,=10 μM), the alkylating agent carmustine exhibited increased cytotoxicity in ovarian cancer cell lines.[85] Studies conducted in pancreatic cancer cells by Jacob et al.